Issue 1, 2015

Macromolecular prodrugs of ribavirin: towards a treatment for co-infection with HIV and HCV

Abstract

Human immunodeficiency virus (HIV) and hepatitis C virus (HCV) represent tremendous healthcare burdens with a large proportion of patients hosting the two viruses at the same time. An altered hepatic function and immunity as well as cross-interference of drugs make treatment of co-infection increasingly challenging. Herein we report the first design of macromolecular prodrugs (MP) with concurrent success in fighting HIV and alleviating hepatitis (liver inflammation). To achieve this, polymer compositions were systematically screened in a broad range of molar mass and content of ribavirin – a broad spectrum antiviral agent. For the first time, we report that ribavirin is efficacious in fighting HIV and in the form of MP, the treatment is safe, both in terms of lack of association of ribavirin with red blood cells and lack of toxicity upon cellular internalization. The lead polymer compositions were also potent in anti-inflammatory assays with relevance to viral hepatitis – thus making up formulations with potential for treatment of co-infection with HIV and HCV.

Graphical abstract: Macromolecular prodrugs of ribavirin: towards a treatment for co-infection with HIV and HCV

Supplementary files

Article information

Article type
Edge Article
Submitted
08 Sep 2014
Accepted
16 Sep 2014
First published
16 Sep 2014
This article is Open Access

All publication charges for this article have been paid for by the Royal Society of Chemistry
Creative Commons BY license

Chem. Sci., 2015,6, 264-269

Author version available

Macromolecular prodrugs of ribavirin: towards a treatment for co-infection with HIV and HCV

A. A. A. Smith, K. Zuwala, M. B. L. Kryger, B. M. Wohl, C. Guerrero-Sanchez, M. Tolstrup, A. Postma and A. N. Zelikin, Chem. Sci., 2015, 6, 264 DOI: 10.1039/C4SC02754J

This article is licensed under a Creative Commons Attribution 3.0 Unported Licence. You can use material from this article in other publications without requesting further permissions from the RSC, provided that the correct acknowledgement is given.

Read more about how to correctly acknowledge RSC content.

Social activity

Spotlight

Advertisements